Role of the Sodium-Dependent Phosphate Cotransporter, Pit-1, in Vascular Smooth Muscle Cell Calcification

Xianwu Li, Hsueh-Ying Yang, Cecilia M. Giachelli

Abstract—Vascular calcification is associated with cardiovascular morbidity and mortality. Hyperphosphatemia is an important contributor to vascular calcification. Our previous studies demonstrated that elevated phosphate induces calcification of smooth muscle cells (SMC) in vitro. Inhibition of phosphate transport by phosphonoformic acid blocked phosphate-induced calcification, implicating sodium-dependent phosphate cotransporters in this process. In the present study, we have investigated the role of the type III sodium-dependent phosphate cotransporter, Pit-1, in SMC calcification in vitro. Human SMC stably expressing Pit-1 small interfering double-stranded RNA (SMC-iRNA) were established using a retroviral system. SMC-iRNA had decreased Pit-1 mRNA and protein levels and sodium-dependent phosphate transport activity compared with the control transduced cells (SMC-CT) (2.9 versus 9.78 nmol/mg protein per 30 minutes, respectively). Furthermore, phosphate-induced SMC calcification was significantly inhibited in SMC-iRNA compared with SMC-CT at all time points examined. Overexpression of Pit-1 restored phosphate uptake and phosphate-induced calcification in Pit-1 deficient cells. Mechanistically, although Pit-1–mediated SMC calcification was not associated with apoptosis or cell-derived vesicles, inhibition of phosphate uptake in Pit-1 knockdown cells blocked the induction of the osteogenic markers Cbfa-1 and osteopontin. Our results indicate that phosphate uptake through Pit-1 is essential for SMC calcification and phenotypic modulation in response to elevated phosphate. (Circ Res. 2006;98:905-912.)

Key Words: sodium-dependent phosphate cotransporter ■ Pit-1 ■ vascular calcification ■ smooth muscle cell

Vascular calcification refers to calcium phosphate deposition in blood vessels, myocardium, and cardiac valves under pathological conditions. Vascular calcification is associated with increased risk of cardiovascular morbidity and mortality. It is highly prevalent in patients with atherosclerosis, diabetes, and renal failure. Approximately 50% of all deaths in end-stage renal disease (ESRD) patients are attributed to cardiovascular diseases. Intimal, as well as medial, calcification contributes to the increased mortality in these patients. Recent evidence indicates that vascular calcification is an actively regulated process, and molecules that inhibit or promote vascular calcification are currently being identified. Mineralization inhibiting molecules appear to play a major role in preventing ectopic calcification under physiological conditions. However, processes that promote calcification may predominate under pathological conditions and are less well defined.

Although the mechanisms of vascular calcification are not fully understood, abnormalities in mineral metabolism are considered important risk factors. In particular, phosphate has emerged as an important regulator of vascular calcification as well as a risk factor for cardiovascular mortality in dialysis patients. In humans, normal levels of serum phosphate range from 1 to 1.5 mmol/L. Hyperphosphatemia, typically observed in patients with ESRD, is defined as serum phosphate levels exceeding 2 mmol/L. In these patients, hyperphosphatemia and elevated calcium×phosphate product are highly correlated with calcification of coronaries, peripheral arteries, and cardiac valves. Importantly, several large epidemiological studies have found that elevated serum phosphate is a major, nontraditional risk factor for cardiovascular mortality in ESRD patients.

The mechanisms that drive vascular calcification are currently under intense investigation. We and others have reported that elevated phosphate induces smooth muscle cell (SMC) calcification in vitro. Concomitant with mineralization, elevated phosphate leads to SMC phenotypic change exemplified by upregulation of osteochondrogenic differentiation markers, such as Cbfa-1 and osteopontin (OPN). Subsequent studies implicated sodium-dependent phosphate cotransporters in phosphate-induced vascular calcification. Inhibition of sodium-dependent phosphate cotransporters by phosphonoformic acid blocked both phosphate-induced phenotypic transition and calcification in vascular SMC. These studies suggested that elevated phosphate, via a sodium-dependent phosphate cotransporter-mediated mechanism, might have direct pro-mineralizing effects on SMC independent of raising the calcium×phosphate product.
The types and mechanisms of sodium-dependent phosphate cotransporter function in vascular calcification are not currently known. Sodium-dependent phosphate cotransporters are glycosylated proteins with 7 to 10 transmembrane-spanning regions. The common function of sodium-dependent phosphate cotransporters is transporting phosphate from the extracellular environment into the cell in a sodium-dependent manner. Three types of sodium-dependent phosphate cotransporters have been identified based on structure, tissue expression, and regulation. The type I and type II sodium-dependent phosphate cotransporters are expressed predominantly in kidney and intestinal epithelium. The type I family includes NaPi-1, RNaPi-1, NPT-1, and Npt-1 and have been identified from various species.19,20 The physiological roles of this family remain to be elucidated. In contrast, the members of the sodium-dependent phosphate cotransporters type II family, including NaPi-2, NaPi-3, NaPi-4, NaPi-5, NaPi-6, and NaPi-7, are crucially involved in renal and intestinal phosphate absorption and play an important role in the maintenance of serum phosphate homeostasis.9,20 The type III sodium-dependent phosphate cotransporters, Pit-1 and Pit-2, are the most recently discovered subtypes and were originally identified as cell surface receptors for the gibbon ape leukemia virus (Glvr-1) and the amphotropic murine retrovirus (Ram-1), respectively.21–23 Type III sodium-dependent phosphate cotransporters are expressed in many tissues and cell types including kidney, brain, heart, liver, lung, osteoblast, and SMC, but their requirement in crucial cellular processes has not yet been determined. In the present studies, we have examined the role of the predominant phosphate cotransporter found in SMC, Pit-1, in phosphate-induced SMC calcification using RNA interference. We provide novel evidence that phosphate transport through Pit-1 plays a critical role in SMC calcification in vitro. In addition, our results further confirm that the modulation of SMC phenotypic change could be one of the mechanisms by which phosphate, via Pit-1, mediates calcification of vascular SMC cultures.

Materials and Methods

Human immortalized aortic SMC (human SMC) were used for experiments. SMC stably expressing Pit-1 small interfering double-stranded RNA (siRNA) were generated using the pSUPER RNA interference system (Oligoengine, Seattle, Wash). Total RNA was isolated from human SMC using the RNeasy kit from Qiagen (Chatsworth, Calif). Reverse transcription was performed using Omniscript Reverse Transcriptase from Qiagen. TaqMan PCR reagents kits and the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, Calif) were used to quantitatively determine levels of human Pit-1, Pit-2, Cbfa-1, and OPN mRNAs. Phosphate uptake assays were performed using H3PO4. Calcium content was determined using the O-cresolphthalein complexone method. Membrane-bound vesicles and apoptotic bodies were isolated from SMC cultures by differential centrifugation and identified by transmission electron microscopy and biochemical marker analysis.

An expanded Materials and Methods section can be found in the online data supplement available at http://circres.ahajournals.org.

Results

Pit-1 Is the Predominant Sodium-Dependent Phosphate Cotransporter Expressed in Human SMC

Our previous studies indicated that sodium-dependent phosphate cotransporters might be involved in phosphate-induced SMC calcification.18 To determine the expression profile of sodium-dependent phosphate cotransporters in human SMC, the abundance of type I, type II, and type III sodium-dependent phosphate cotransporters were determined initially using RT-PCR. Using this technique, no bands were obtained using primers for NPT1 (human type I family) and NaPi-3 (human type II family) (data not shown). However, a strong band at 409 bp was obtained using Pit-1 primers, and a weaker band at 384 bp was amplified using Pit-2 primers (Figure 1A), indicating that members of the human type III family were present. Sequence analysis of these amplified fragments confirmed their identities as human Pit-1 and Pit-2, respectively (data not shown). Similar results were obtained in primary human aortic SMC (data not shown). Real-time PCR was used to precisely quantitate the expression levels of Pit-1 and Pit-2 in the cells. As shown in Figure 1B, the Pit-1 mRNA levels were 8-fold higher than that of Pit-2 in human SMC. These results indicated that Pit-1 is the predominant form of sodium-dependent phosphate cotransporter expressed in human SMC. Therefore, subsequent experiments focused on determining the role of Pit-1 in human SMC calcification.

Downregulation of Pit-1 mRNA Leads to Decreased Pit-1 Protein Levels in Human SMC

Previous studies using phosphonomiform acid, a generic sodium-dependent phosphate cotransporter inhibitor, implicated a crucial role for these cotransporters in phosphate-mediated SMC calcification.19 To more specifically address the role of Pit-1 in this process, RNA interference was used to
suppress endogenous Pit-1 mRNA levels. SMC stably expressing Pit-1 siRNA (SMC-iRNA) or control construct (SMC-CT) were established using a retroviral system. Effects on Pit-1 expression levels were examined by Northern and Western blot analysis. As shown in Figure 2A and 2B, Pit-1 mRNA levels were dramatically reduced (80%) in SMC-iRNA compared with levels in SMC-CT. Western blotting confirmed a comparable decrease in Pit-1 protein levels in SMC-iRNA (Figure 2C and 2D).

To determine the specificity of the Pit-1 siRNA, mRNA levels of 2 other membrane transporters, Pit-2 and sodium hydrogen antporter (NHA), were measured. Pit-2 is the other member of type III sodium-dependent phosphate cotransporter family and shares 58% homology at the amino acid level with Pit-1.22 Despite this sequence similarity, Pit-1 siRNA had no effect on Pit-2 mRNA levels. Similarly, NHA mRNA was not inhibited by Pit-1 siRNA (Figure 2A and 2B). These results demonstrated that the Pit-1 siRNA specifically inhibited Pit-1 expression.

**Inhibition of Sodium-Dependent Phosphate Uptake by Pit-1 siRNA**

To determine whether decreased Pit-1 mRNA and protein levels translated to decreased Pit-1 function, phosphate uptake assays were performed in SMC-iRNA and SMC-CT. As shown in Figure 3A and 3B, phosphate uptake was concentration and time-dependent in both cell types. However, overall phosphate uptake was substantially decreased in SMC-iRNA compared with SMC-CT at all concentrations (at 30 minutes in 1.5 mmol/L Pi, SMC-iRNA versus SMC-CT: 2.90 versus 9.78 nmol/mg protein, respectively). Likewise, phosphate uptake was substantially decreased in SMC-iRNA compared with SMC-CT at all time points (at 120 minutes in 0.1 mmol/L Pi, SMC-iRNA versus SMC-CT: 11.27 versus 21.90 nmol/mg protein, respectively). These results indicated that a decrease in cellular Pit-1 levels caused by the Pit-1 siRNA resulted in a comparable decrease in phosphate uptake. No effect on sodium-independent phosphate transport was observed (data not shown).

**Inhibition of SMC Calcification by Pit-1 siRNA**

To determine whether Pit-1 knockdown affected the ability of human SMC to calcify, both SMC-iRNA and SMC-CT were
incubated with either growth media (GM) (1.4 mmol/L phosphate) or calcification media (CM) (2.6 mmol/L phosphate) for 7, 10, and 14 days, and calcification was determined biochemically and histologically. As shown in Figure 4A, SMC-iRNA showed significantly less calcium deposition than SMC-CT at all time points (at day 10, SMC-iRNA versus SMC-CT: 71.84 versus 163.09 μg/mg protein, respectively). Mineral deposits were further identified morphologically by Von Kossa staining and light microscopy. As shown in Figure 4B, after culture in CM for 10 days, abundant mineral deposits associated with extracellular matrix could be detected throughout the SMC-CT culture. Comparable to biochemical data, much less mineral deposition was observed in SMC-iRNA compared with SMC-CT. No mineral deposits were observed in cultured SMC treated with GM at any time points (data not shown). These results suggested that Pit-1 was necessary for SMC calcification induced by elevated phosphate in vitro.

**Restoration of Calcification by Overexpression of Mouse Pit-1 in Pit-1 Deficient Human SMC**

To further determine the specific requirement of Pit-1 in SMC calcification and to rule out potential off-target effects of Pit-1 siRNA, we examined whether overexpression of Pit-1 could restore phosphate-induced calcification in SMC-iRNA. To do this, we took advantage of a 3-bp mismatch between human and mouse Pit-1 in the siRNA targeting region. Thus, the human Pit-1 siRNA is unable to target the mouse Pit-1 transcript for degradation. Retroviral constructs encoding mouse Pit-1 cDNA or empty vector pLXIN were, therefore, generated and used to infect SMC-iRNA. The transduced cells are referred to as SMC-mPit1 or SMC-LXIN, respectively. Mineral deposits were further identified morphologically by Von Kossa staining and light microscopy. As shown in Figure 4B, after culture in CM for 10 days, abundant mineral deposits associated with extracellular matrix could be detected throughout the SMC-CT culture. Comparable to biochemical data, much less mineral deposition was observed in SMC-iRNA compared with SMC-CT. No mineral deposits were observed in cultured SMC treated with GM at any time points (data not shown). These results suggested that Pit-1 was necessary for SMC calcification induced by elevated phosphate in vitro.

**Figure 4. Effect of Pit-1 siRNA on phosphate-induced calcification in SMC.** A, SMC-iRNA and SMC-CT were cultured in CM for the indicated times. The calcium content was measured by O-cresolphthalein complexone method and normalized by the protein content. Data shown are means±SD (n=3). *Significant decrease (P<0.05) compared with SMC-CT. B, SMC-iRNA, SMC-CT, and SMC-mPit1 were cultured in CM for 10 days. After incubation, the cells were fixed with 4% paraformaldehyde. Mineral deposition was visualized by Von Kossa staining. The sections were counterstained with toluidine blue.

**Figure 5. Effect of Pit-1 overexpression on sodium-dependent phosphate uptake and calcification in SMC.** A, RT-PCR analysis of mouse Pit-1 expression. Total RNA was isolated from SMC-mPit1 or SMC-LXIN. PCR was performed with primers for mouse Pit-1 or GAPDH as an internal control. An expected 406-bp fragment of mouse Pit-1 was detected. B, Phosphate uptake was determined by incubation of SMC with 0.1 mmol/L phosphate for 30 minutes as described in Materials and Methods. Data shown are means±SD (n=3). C, Cells were cultured in CM for 10 days. The calcium content was measured by O-cresolphthalein complexone method and normalized by the protein content. Data shown are means±SD (n=3). *Significant increase (P<0.05) compared with SMC-LXIN.
was almost twice as high in SMC-mPit1 compared with SMC-LXIN (SMC-mPit1 versus SMC-LXIN: 179.84 versus 103.44 μg/mg protein, respectively). Furthermore, the calcium content in SMC-mPit1 was almost the same as SMC-CT (SMC-mPit1 versus SMC-CT: 179.84 versus 194.14 μg/mg protein, respectively). Von Kossa staining revealed that overexpression of mPit-1 increased the formation of mineral deposits in the extracellular matrix of cultured SMC, and the levels of calcification in these cells were comparable to that of SMC with normal Pit-1 levels (Figure 4B). Taken together, these results suggest that Pit-1 is an important mediator of calcification in SMC.

Pit-1 Is Not a Component of Matrix Vesicles or Apoptotic Bodies Derived From SMC

One possible mechanism for the requirement of Pit-1 in SMC calcification is in mediating phosphate loading of calcifying extracellular vesicles. Growing evidence suggests that membrane-bound vesicles derived from cells may be involved in both physiological and pathological calcification. In bone and cartilage, matrix vesicles have been identified as cell-derived, membrane-bound vesicles intimately associated with sites of active extracellular matrix mineralization.24 In addition, Shanahan and colleagues have described calcifying membrane-bound vesicles and apoptotic bodies released from human aortic SMC cultured in serum-free media (SFM).25 In both cases, it is postulated that these membrane-bound vesicles participate in mineralization by concentrating calcium and phosphate in a protected microenvironment, thereby promoting mineral nucleational events.

To determine whether Pit-1 was a component of SMC-derived vesicles, we used two different methods to isolate membrane-bound vesicles from cultured SMC. In the first approach, the classic collagenase method for isolation of matrix vesicles from bone and cartilage was used.26 As shown in Figure 6A, transmission electron microscopy revealed that vesicles derived from the extracellular matrix of human SMC were membrane bound and heterogeneous in shape and size, with diameters ranging from 100 to 200 nm, identical to those described from chondrocyte cultures.27 Equivalent amounts of matrix vesicles, as determined by protein content, were isolated from SMC cultured in CM compared with in GM (CM versus GM: 2.9 versus 3.0 mg/mL protein respectively). Western blot analysis demonstrated that these vesicles contained Annexin V (Figure 6B), a previously identified marker of matrix vesicles.24 Annexin V levels were identical in matrix vesicles isolated from human SMC cultured in GM or CM, suggesting again that elevated phosphate treatment does not alter matrix vesicle formation or protein content. However, no Pit-1 protein was detected in these matrix vesicle preparations under either normal or elevated phosphate conditions (Figure 6B), suggesting that Pit-1 was not involved in phosphate loading by these structures.

In the second approach, membrane-bound vesicles and apoptotic bodies were isolated from apoptotic human SMC following serum starvation under normal (SFM) or elevated calcium and phosphate conditions (CPM), as previously described.25 Identical to results obtained with matrix vesicles, Pit-1 was not detected in these apoptotic vesicle preparations under any condition examined (Figure 6C).

Pit-1 Does Not Promote SMC Apoptosis in Response to Elevated Phosphate

Previous studies have shown that apoptosis can accelerate mineralization in serum-deprived and long-term cultured human SMC.25,28 Thus, another possible mechanism for elevated phosphate- and Pit-1–mediated SMC calcification might be through stimulation of apoptosis. To determine whether elevated phosphate induced SMC death via Pit-1, we examined apoptosis in SMC-iRNA cells and SMC-CT cells. Both cells were cultured in GM or CM and apoptosis was detected by specific ELISA to monitor mono- and oligonucleosomal chromatin formation. As shown in Figure 7A, very little apoptosis was detected in both cell types when cultured in GM. Importantly, treatment of the SMC-CT cells with CM did not increase apoptosis, and identical results were obtained in SMC-iRNA cells. As expected, treatment of cells with SFM overnight strongly induced apoptosis, and levels were similar in SMC-CT and SMC-iRNA cells (Figure 7A). Finally, treatment of human SMC with 100 μmol/L zVAD, a potent caspase inhibitor, did not inhibit elevated phosphate-induced calcification (Figure 7B). These results indicate that the phosphate concentrations used in the present studies do not stimulate SMC apoptosis and that cells deficient in Pit-1 (SMC-iRNA) are not less susceptible to cell death than cells containing normal levels of Pit-1 (SMC-CT). Thus, apoptosis is unlikely the mechanism for Pit-1 mediated SMC calcification.

Pit-1 Is Required for Elevated Phosphate-Induced Osteogenic Gene Expression in Human SMC

We and others have previously shown that elevated phosphate stimulates SMC calcification concomitant with pheno-
typic change, characterized by expression of osteogenic genes such as Cbfa-1 and OPN. To determine whether Pit-1 was required for elevated phosphate-induced SMC phenotypic transition, we examined Cbfa-1 and OPN mRNA levels in SMC-CT and SMC-iRNA using real-time PCR. As expected, both Cbfa-1 and OPN mRNA levels were significantly induced by elevated phosphate relative to normal phosphate conditions in SMC-CT at 7 days following treatment (Figure 8A and 8B). In contrast, Cbfa-1 and OPN mRNA levels did not increase in response to elevated phosphate treatment compared with normal phosphate conditions in SMC-iRNA. Similar results were obtained when SMC-CT and SMC-iRNA were incubated with elevated phosphate for 2 days (data not shown). These results suggest that Pit-1 was required for expression of Cbfa-1 and OPN mRNA in human SMC in response to elevated phosphate conditions.

Discussion

Previous studies indicated that elevated phosphate could induce SMC calcification as well as an osteochondrogenic phenotypic change in vitro. Blocking the activity of sodium-dependent phosphate cotransporters with the nonspecific inhibitor phosphonoformic acid inhibited SMC calcification, suggesting an important role for phosphate uptake in SMC calcification. In the present study, we examined the requirement for the major sodium-dependent phosphate cotransporter in SMC, Pit-1, in calcification using RNA interference and overexpression approaches. We found that stable expression of Pit-1 siRNA specifically inhibited Pit-1 mRNA and protein levels and led to a dramatic decrease in sodium-dependent phosphate uptake in SMC. Furthermore, calcification in response to elevated phosphate was substantially inhibited in SMC stably expressing Pit-1 siRNA. Subsequent restoration of phosphate uptake by overexpression of Pit-1 in Pit—deficient SMC rescued phosphate-induced calcification.

The present studies confirm the concept that vascular calcification is a highly cell-regulated process. This idea has been highlighted recently by the identification of several local and systemic, cell-derived inhibitors of calcification, such as osteopontin, pyrophosphate, and matrix gla protein, whose deficiency leads to inappropriate vascular calcification in vivo and in vitro. In addition to negative regulators, a growing number of positive regulators of calcification, such as lipids, cytokines, and elevated phosphate levels, have also been identified. Induction of SMC calcification by elevated phosphate is of particular interest, because hyperphosphatemia is a major risk factor for vascular calcification in dialysis patients. In the present studies, modulation of the levels of a cell membrane transporter, Pit-1, controlled the susceptibility of SMC to calcification in the presence of elevated phosphate. Despite equivalent calcium and phosphate levels in the culture media, cells that were deficient in Pit-1 had substantially reduced extracellular matrix calcification compared with cells with normal levels of Pit-1. These
findings strongly suggest that cellular mechanisms, including phosphate uptake and/or signaling via Pit-1 is required for SMC calcification.

To begin to understand the mechanism(s) whereby Pit-1 mediates human SMC calcification in response to elevated phosphate, we considered several possibilities. First, we hypothesized that Pit-1 might be important for phosphate loading of calcifying membrane-bound vesicles, such as matrix vesicles and/or apoptotic bodies, that have been implicated in both physiological and pathological mineralization. There is considerable evidence suggesting the important role of matrix vesicles in the mineralization of bone and cartilage by concentrating calcium and phosphate and initiating mineral nucleation.24 In addition, a recent study by Shanahan and colleagues identified membrane-bound vesicles containing apoptotic bodies from apoptotic human SMC that could calcify after prolonged exposure to elevated calcium or phosphate.25 Although matrix vesicles as well as apoptotic bodies could be isolated from human SMC in the present study, we were unable to detect Pit-1 protein in either preparation, regardless of culture under normal or elevated phosphate conditions. Furthermore, equivalent numbers of matrix vesicles and apoptotic bodies were isolated in normal and elevated phosphate containing media. Thus, it is unlikely that Pit-1 mediates calcification of human SMC by facilitating synthesis, release, or phosphate loading of matrix vesicles or apoptotic bodies.

Next, we tested the hypothesis that Pit-1 might be required to induce apoptosis in human SMC in response to elevated phosphate treatment, thereby promoting calcification. Previous studies suggested that extremely high phosphate levels (4 to 10 mmol/L) induced apoptosis in chondrocytes as well as SMC and that mineralization was mediated, in part, through apoptosis-dependent mechanisms.25,28,34,35 In the present studies, human SMC cultured in serum-containing media in the presence of 2.6 mmol/L phosphate did not show increased apoptosis compared with cells cultured in normal phosphate containing media (1.4 mmol/L phosphate). Furthermore, cells deficient in Pit-1 had very low levels of apoptosis that were comparable to cells with normal Pit-1 levels, and the susceptibility of these cells to apoptosis was not altered by elevated phosphate treatment. Finally, the caspase inhibitor zVAD failed to prevent phosphate-induced calcification in our system. These results suggest that phosphate-induced apoptosis is not the mechanism by which elevated phosphate induces SMC calcification under our culture conditions. These findings are in contrast to Reynolds et al, who showed that elevated calcium (2.7 mmol/L) combined with elevated phosphate (2.0 mmol/L) induced apoptosis as well as calcification of human SMC cultured in SFM.25 The difference in these findings is most likely explained by differences in culture conditions. Reynolds et al used SFM combined with elevated calcium and phosphate to induce SMC apoptosis, apoptotic body formation, and calcification, whereas the human SMC in our studies were cultured in serum-containing media, with calcium and phosphate levels kept well below concentrations that could result in spontaneous mineral precipitation in solution or cause apoptosis. Indeed, incubation of human SMC in SFM strongly induced apoptosis in our study as well. Thus, the requirement of Pit-1 in human SMC calcification under the more physiological conditions of our system does not appear to be via a mechanism involving altered apoptosis.

Finally, we hypothesized that phosphate uptake through Pit-1 was required for the phenotypic modulation of human SMC to an osteochondrocytic phenotype, thereby regulating the mineralization capacity of these cells. In support of this hypothesis, human SMC deficient in Pit-1 failed to upregulate Cbfa-1 and OPN mRNA levels in response to elevated phosphate treatment. In contrast, both genes were induced in human SMC containing normal levels of Pit-1, consistent with previous findings.15,18 Of interest, Pit-1 has also been implicated in bone cell differentiation and mineralization. Pit-1 mRNA increases during osteoblast differentiation and correlates with the time at which calcification is observed.36 Likewise, studies by Palmer et al found that Pit-1 mRNA was expressed in mineralizing, hypertrophic chondrocytes from day 17 in embryonic murine metatarsals, whereas no Pit-1 mRNA was detected in fully differentiated, nonmineralized chondrocytes.37 Thus, phosphate uptake via Pit-1 may be a major regulator of cellular differentiation programs involved in both normal and pathological calcification.

In summary, knockdown of Pit-1 expression by siRNA inhibited sodium-dependent phosphate uptake as well as phosphate-dependent SMC calcification. Restoration of phosphate uptake by overexpression of Pit-1 in Pit-1-deficient cells rescued calcification. Our results indicate that phosphate uptake is required for SMC calcification induced by elevated phosphate. Our studies also suggest that Pit-1-dependent SMC calcification is not mediated by enhanced apoptosis or membrane-bound vesicle phosphate loading. However, inhibition of phosphate uptake in Pit-1 knockdown cells did abrogate induction of osteogenic markers, such as Cbfa-1 and OPN, in human SMC. These findings demonstrate a requirement for phosphate uptake via the sodium-dependent phosphate cotransporter, Pit-1, for SMC phenotypic transition and calcification that is likely to be important in the development of ectopic calcification of blood vessels under hyperphosphatemic conditions. These studies also point to Pit-1 as a potential target for therapies aimed at reducing vascular calcification.

Acknowledgments
This work was supported by NIH grant HL-62329. We thank the University of Washington Engineered Biomaterials (UWEB) Optical Microscopy and Image Analysis Shared Resource, funded by the National Science Foundation through grants EEC-9872882 and EEC-9529161.

References


Role of the Sodium-Dependent Phosphate Cotransporter, Pit-1, in Vascular Smooth Muscle Cell Calcification
Xianwu Li, Hsueh-Ying Yang and Cecilia M. Giachelli

Circ Res. 2006;98:905-912; originally published online March 9, 2006;
doi: 10.1161/01.RES.0000216409.20863.e7

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/98/7/905

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2006/03/09/01.RES.0000216409.20863.e7.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
Materials and Methods

Cell Culture

Human aortic SMC (human SMC) were isolated, characterized, and immortalized as previously described. Primary human aortic SMC were obtained from Clonetics Corporation (Palo Alto CA). Cells were routinely cultured in growth media (GM, DMEM containing 15% FBS, 1.4 mmol/L phosphate, 100 U/mL of penicillin and 100 mg/mL of streptomycin). For elevated phosphate conditions, GM was supplemented with NaH$_2$PO$_4$/Na$_2$HPO$_4$ to a final concentration of 2.6 mmol/L (calcification media, CM).

Preparation of Stable SMC Expressing Pit-1 Small Interfering RNA (siRNA)

The pSUPER RNA interference system (Oligoengine, Seattle, WA) was used to generate SMC stably expressing Pit-1 siRNA. Briefly, oligonucleotides for human Pit-1 (5’GCCTGAAGTATCTCTCCTC3’) or Pit-1 control (5’TCCAGAGGTATGCCACATA3’) were obtained from MWG Biotech Inc (High Point, NC). The annealed double-stranded oligonucleotides were inserted into the pSUPER retrovirus vector, and recombinant constructs were transfected into Phoenix packaging cells to generate retrovirus. The infection of SMC was performed using polybrene by exposure to retrovirus for 1 h every 24 h for three consecutive days. The infected cells were selected with 3 µg/ml puromycin for 72 h. SMC containing Pit-1 siRNA are hereafter referred to as SMC-iRNA, whereas the SMC containing the Pit-1 control construct are referred to as SMC-CT.
Reverse Transcription PCR and Preparation of cDNA Probes

Total RNA was isolated from cultured SMC using RNeasy kit from Qiagen (Chatsworth, CA). Reverse transcription was performed using First-Strand cDNA Synthesis kit (Amersham Biosciences UK, England). The primers used for PCR amplification were: 1) Human Pit-1 forward 5'-TACCATCCTCATCTCGGTGG-3' and reverse 5'-TGACGGCTTGACTGAAGTGG-3', the amplified fragment corresponds to base pairs 1060 - 1469 of human Pit-1 (L20859). 2) Human Pit-2 forward 5'-TGGATGGTCATTTTGGGTTT-3' and reverse primer 5'-GCACACCTTTGTACCGATT-3’, the amplified fragment corresponds to base pairs 265-649 of human Pit-2 (L20852). 3) Mouse Pit-1 forward 5'-TACCATTCTATCTCGGTGG-3' and reverse 5'-TGACAGTTTGACTGAACTG -3’. The PCR product is 406 base pairs and corresponds to position 1111-1517 of mouse Pit-1 (M73696). 4) Human sodium hydrogen antiporter (NHA) forward 5'-GATCCTTCTGGCCTGCCTCA-3' and reverse primer 5'-TCAGGATGTTGCCACAGGTTT-3’, which corresponds to base pairs 377-624 of the human NHA (M81768). The amplified fragments were obtained by RT-PCR from the mRNA of SMC, and then subcloned into the TA cloning vector (Invitrogen, Carlsbad, CA) previously described.\(^1\) The identity of the cDNA inserts as Pit-1, Pit-2 or NHA was confirmed by DNA sequence analysis.

Cloning and Expression of Mouse Pit-1

Full-length mouse Pit-1 cDNA was cloned from mouse aortic SMC by RT-PCR, using the forward primer 5’ GGATCCATGGAATCTACTGTGGCAACG -3’ and the reverse
primer 5'-CTCGAGTCACACTGGCAGGATGATGT-3'. The PCR product was cloned into the EcoR I site of the retroviral expression vector pLXIN (BD Biosciences, Palo Alto, CA). Recombinant pLXIN containing mouse Pit-1 cDNA or empty vector were transfected into the Phoenix packaging cell line by calcium-phosphate precipitation to generate retrovirus. Retroviral infection of SMC-iRNA was performed as described above. The transduced cells containing mouse Pit-1 or empty vector were referred to as SMC-mPit1 or SMC-LXIN respectively. Pooled populations of cells were used for experiments.

**Quantitative Real-Time PCR**

Total RNA was isolated from human SMC using the RNeasy kit from Qiagen (Chatsworth, CA). Reverse transcription was performed using Omniscript Reverse Transcriptase from Qiagen. Levels of human Pit-1, Pit-2, Cbfa-1 and OPN mRNAs were determined by quantitative real-time PCR performed with TaqMan PCR reagents kits in the ABI Prim 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). The primers and probes were designed using Primer-Express software V2.0 (Applied Biosystems). The primers were synthesized by Qiagen and the Taq probes were obtained from the Applied Biosystems. All of the Taq probes have a FAM (fluorochrome reporter) tag at the 5’-end and an MGB quencher at the 3’-end and the sequences are: 1) Human Pit-1 forward 5’-GGAGGGTGTCAAGTGGTCTGAA-3’ and reverse 5’-ATCTGCCTTATGGAGGATGAATG -3’, the probe 5’-CTGATAAAAATTGTGATGATCTTTTG-3’. 2) Human Pit-2 forward 5’-forward-
TACAACGAGACGGTGGAGACTCT-3' and reverse 5’-
AAGCAATCAGCTGCCACACA-3’, the probe 5’-CCATGGTGGTGTCCG-3’.
3) Human Cbfa-1 forward 5’- CCCGTGGCCTTCAAGGT-3’ and reverse 5’-
TGACAGTAACCACAGTCCCATCTG-3’, the probe 5’-AGCCCTCGGAGAGGT-3’. 4) Human OPN forward 5’- TGTCCTCTGAAGAAACCAATGACTT -3’ and reverse 5’-
TCATGGCTTTTCGTTGGACTTACT -3’, the probe 5’-AAACAAGAGACCCTTCC -3’. All PCR reactions were performed in triplicate. Quantification of gene expression was calculated by the standard curve method according to the manufacturer’s protocol and normalized to 18S rRNA.

**Northern Blot Analysis**
Total RNA was isolated from SMC with Trizol (Invitrogen Inc., Carlsbad, CA). Total RNA was electrophoresed, transferred to a Zeta-probe blotting membrane (Bio-Rad Laboratories, Hercules, CA), and hybridized with \( ^{32}P \)-labeled cDNA probes for human Pit-1, Pit-2 or NHA as previously described.\(^1\) Relative mRNA levels were quantified by densitometric scanning and normalized to 18S rRNA. The sequence of 18S rRNA probe was described previously.\(^2\)

**Phosphate Uptake Assays**
Phosphate uptake assays were performed as previously described.\(^1\) In brief, SMC were incubated in Earle’s buffered salt solution (EBSS) containing various concentrations of phosphate (including \( \text{H}_3^{32}\text{PO}_4 \) obtained from PerkinElmer Life Science, Inc. Boston, MA). Sodium-dependent phosphate uptake was determined by subtracting uptake in the
presence of EBSS containing choline chloride from uptake in EBSS containing sodium chloride. Uptake values were normalized to cellular protein content.

**Calcium Quantitation**

SMC calcification was induced by the treatment with calcification media (CM, 2.6 mmol/L phosphate). Calcium content of the cultures was determined using the O-cresolphthalein complexone method exactly as previously described\(^1\) and normalized to protein content.

**Western Blot Analysis**

Cell lysates were prepared as described previously.\(^2\) Equal amounts of protein were loaded and separated by 8% SDS-PAGE followed by transfer to PVDF membrane. The membranes were then blotted using anti-Pit-1 or anti-Annexin V antibodies (R&D System, Minneapolis, MN). Pit-1 antibody was obtained by immunizing rabbits with the Pit-1 peptide, QAVVEERTVSKDLEERPLSVDLKEETSIDSTV, followed by peptide affinity purification of serum using Sulfo-Link kit from Pierce Biotechnology, Inc. (Rockford, IL). Specific proteins were detected with enhanced chemiluminescence reagents (Perkin Elmer Life Science, Inc. Boston, MA).

**Membrane-bound Vesicle Isolation**

Membrane-bound, extracellular vesicles were prepared by two different methods as described previously.\(^3,4\) For extracellular matrix-derived vesicles, after 2 day incubation with normal growth media (GM, containing 1.4 mmol/L phosphate) or calcification
media (CM, containing 2.6 mmol/L phosphate), SMC monolayers were washed and then incubated with 500 U/ml of collagenase for 3 hours at 37°C. The digest was centrifuged for 20 mins at 15,000g to pellet cell debris. The supernatant was centrifuged for 60 min at 100,000g. The resulting pellet containing extracellular matrix-derived vesicles was resuspended and used for subsequent experiments. Alternatively, SMC were incubated overnight with either serum-free media (SFM, serum-free GM supplemented with 0.5% BSA) or elevated calcium and phosphate containing media (CPM, serum-free media with 2.7 mmol/L calcium and 2.0 mmol/L phosphate). The culture medium was collected and centrifuged for 20 min at 2500 rpm to remove the debris, the supernatant (containing shed membrane-bound vesicles) was then spun for 30 min at 100,000g.

**Apoptosis Assay**

The Cell Death Detection ELISA kit (Roche Diagnostics Co, Indianapolis, IN) was used according to the manufacturer’s direction to quantitatively determine cytoplasmic histone-associated DNA oligonucleosome fragments associated with apoptotic cell death.5

**Statistical Analysis**

Results are expressed as mean ± SD. Significance between groups was determined by ANOVA, p-values less than 0.05 were considered significant.
References


